AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

Back in May, health data company Datavant announced its plans to acquire Aetion, creating a formidable player in the ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

This pricing shock immediately exposed pharma’s second crisis: R&D costs that continue to climb, now between $0.8 and $2.8 ...

In a sector where trust is critical, and attention is limited, that feeling matters. Frictionless design isn’t just about ...

Johnson & Johnson’s Janssen-Cilag has secured European Commission approval for a new indication of its subcutaneous ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting appointments on the non-profit side.

The Evolution Summit is designed to address the most pressing challenges and opportunities in clinical trials, with a focus ...